“…Neither an activator of adenylate cyclase, forskolin (Seamon et al, 1981), nor an inhibitor of adenylate cyclase, MDL 12,330A (Hunt & Evans, 1980) modified the inhibitory effect of adenosine on neuromuscular transmission. The finding that PDAc increases the amplitude and the quantal content of e.p.ps, and thus increases evoked transmitter release, conforms with the results obtained by others using phorbol esters active on protein kinase C either at the neuromuscular junction (Haimann et al, 1987;Shapira et al, 1987;Caratsch et al, 1988) or the central nervous system (Zurgil et al, 1986;Nichols et al, 1987;Huang et al, 1988;Fredholm & Lindgreen, 1988). The enhancement of neuromuscular transmission caused by PDAc, as well as its ability to attenuate the inhibitory effect of adenosine receptor agonists at the neuromuscular junction, might be related to its ability to activate protein kinase C, since (1) the effective concentrations of PDAc at the neuromuscular junction are within the order of magnitude of its affinity for the enzyme (Leach et al, 1983), and (2) the phorbol ester inactive on protein kinase C, PDDec (Castagna et al, 1982), used in a concentration more than 100 times higher than the affinity constant of its active stereoisomer (Leach et al, 1983), did not modify the amplitude of the e.p.ps or the inhibitory action of adenosine on neuromuscular transmission.…”